X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds for continued research and development and commercialization activities of its lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 06, 2024
Details:
The Company intends to use the net proceeds for continued research and development and commercialization activities of its lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2024
Details:
The Company intends to use the proceeds for continued research and development and commercialization activities of its lead candidate CTx-1301, a novel, trimodal formulation of dexmethylphenidate to treat ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 13, 2023
Details:
The proceeds will fund for continued R&D and commercialization activities of company's lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a once-daily stimulant medication for attention-deficit/hyperactivity disorder.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 11, 2023
Details:
CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Vince Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
CTx-1301 (dexmethylphenidate) is a sustained release and immediate-release tablet part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2023
Details:
CTx-1301, utilizes the Company’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Under the agreement, Indegene will provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit/hyperactivity disorder.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Indegene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 13, 2023
Details:
CTx-1301 (dexmethylphenidate) is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. It is being developed for ADHD.
Lead Product(s): Dexmethylphenidate
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-1301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
